Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignanciesKazuyuki Mizuno, Mitsuhiro Fujishiro, Takashi Honda et al.|Journal of Gastroenterology|2020Cited by 74
Sorafenib <i>vs</i>. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor ThrombosisTeiji Kuzuya, Mitsuhiro Fujishiro, Masatoshi Ishigami et al.|Anticancer Research|2020Cited by 53
Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatmentTeiji Kuzuya, Mitsuhiro Fujishiro, Masatoshi Ishigami et al.|Hepatology Research|2019Cited by 51
Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular CarcinomaTeiji Kuzuya, Mitsuhiro Fujishiro, Masatoshi Ishigami et al.|Anticancer Research|2020Cited by 44
Sarcopenia impairs health-related quality of life in cirrhotic patientsYusuke Ando, Mitsuhiro Fujishiro, Masatoshi Ishigami et al.|European Journal of Gastroenterology & Hepatology|2019Cited by 41